TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04444050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo, Matching BMS-986331
Description: Specified dose on specified days
Study: NCT03227497

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whole Walnuts
Description: Intervention arm includes whole walnuts taken as dietary replacement meal during the day, and between breakfast and lunch, and/or lunch and dinner. Importantly, none of the main meals, including breakfast, lunch and dinner are to be replaced by study intervention, and the study subjects are instructed to do so. Walnuts are provided with the same producer at the Belgrade market.
Study: NCT02435043

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nature based rehabilitation
Description: ten weeks of nature-based rehabilitation, as add-on to standard management. A rehabilitation program in groups up to 8 patients in an especially designed garden at the Swedish University of Agricultural Sciences, Alnarp. The intervention was grounded in environmental psychology and occupational therapy, supported by a multimodal rehabilitation team that utilized the garden/nature for sensory stimulation, body awareness, meaningful occupations and nature experiences.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard management after stroke
Description: standard management after stroke is individualised.
Study: NCT02769494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine Sustained-Release Tablets
Description: Mesalazine sustained-release tablets 500mg and 0.02L glycerol mixed, the preparation of 2.5% the mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riboflavin Sodium Phosphate Injection
Description: gently apply the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
Study: NCT03161158

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CHIARA-System
Description: Treatment with veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm. 1-7 Ultrafiltration sessions (6-10h/session, number of sessions depending on clinical assessment) for at least 1-2 consecutive days and a maximum of 7 days.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care IV diuretics
Description: Guideline-directed therapy including IV loop diuretics (according to treatment algorithm)
Study: NCT03989648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Esmarch bandages
Description: Esmarch bandage (also known as Esmarch's bandage for surgical haemostasis or Esmarch's tourniquet) in its modern form is a narrow (5 to 10 cm wide) soft rubber bandage that is used to expel venous blood from a limb (exsanguinate) that has had its arterial supply cut off by a tourniquet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: simple leg elevation
Description: simple leg elevation 45 degree for 2 minutes is used to expel venous blood from a limb
Study: NCT03883412

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16 weeks of treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 16 weeks of treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 16 weeks of Liraglutide
Study: NCT00291343

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™
Description: One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mencevax™ ACWY
Description: One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mencevax™ ACWY
Description: One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months
Study: NCT01209715

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will be assigned to 3-weeks treatment of inhaled placebo twice a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone /salmeterol
Description: Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone /salmeterol
Description: Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
Study: NCT02016287

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy
Description: Sequential paclitaxel chemotherapy and radiotherapy
Study: NCT01662999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Study: NCT03883412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: 16 weeks of Liraglutide
Study: NCT01569269

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Intervention
Description: The yoga intervention will take place for one hour per week for six weeks. All sessions will be guided by a Registered Yoga Teacher (RYT) who is also a Licensed Clinical Social Worker (LCSW).~Each yoga session will follow a similar protocol. The introductory period (10 minutes) will focus participants on increasing interoceptive and proprioceptive capacity. The main segment is comprised of a series of yoga postures that progress from lying or seated postures that provide gentle muscle stretching to standing stretches that increase balance and flexibility. The postures will be introduced, practiced, and combined with breathing exercises for forty minutes.~The conclusion of the session will be comprised of 10 minutes of relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation Intervention
Description: The meditation intervention will be conducted weekly for weeks. Each class will follow a similar protocol: During the one-hour meeting, participants will focus on developing attention to the breath. In a supine or seated position and with eyes closed, participants will be guided to attend solely to their breathing. As physical sensations, thoughts, and emotions begin to arise, participants will be taught to recognize, acknowledge, and accept the presence of the sensations or emotions and then to step back, release the thought or sensation, and refocus attention toward the breath At the conclusion of each meeting, the meditation instructor will encourage participants to voluntarily engage in daily meditation practices.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reiki
Description: The Reiki intervention will be conducted for one hour per week for 6 weeks. Protocol for each session: Briefly meet with the Reiki practitioner to review experiences with symptoms of CIPN. Then, the participant will be directed to lie supine and fully clothed on a massage table. Beginning at the top of the head, the practitioner will move inferiorly and pause while holding their hands above, but facing the participant at each energy point until reaching the feet. Upon reaching the participant's feet, the participant will roll from the supine position to a prone position and the process repeated. After being guided to a seated position on the massage table, the practitioner will spend a few moments in conversation with the participation before ending the session.
Study: NCT01537107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vismodegib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: Given PO
Study: NCT01569269

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Holistic Education
Description: The psychoeducational intervention will be presented in a traditional classroom format with weekly one hour meetings taking place during the six week study period. Each class meeting will address specific aspects of CIPN. Participants will be presented with content related to basic neuroanatomy, physiology, the effects of chemotherapy on peripheral nervous system, how available allopathic treatments (pharmacological/psychopharmacological) can be helpful, and psychosocial issues related to CIPN. The final week of the psychoeducational group will include the identification of complementary interventions that may be of help to people living with CIPN.
Study: NCT02632344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
Study: NCT01695538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The subjects will be asked to practice Yoga poses at least 3 times a week at home, although daily Yoga will be encouraged. Participants will be trained in breathing exercises, postures and meditation. Each time they practice yoga will be for 1 hour and include breathing exercises, postures and meditation.
Study: NCT00194454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified cognitive behavioral therapy plus problem-solving
Description: 9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
Study: NCT02451267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy treatment with aerobic exercise
Description: neck exercise strengthening program with neck massage and aerobic exercise (leg bicycling with relaxed shoulders)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy treatment with aerobic exercise
Description: neck exercise strengthening program with neck massage and aerobic exercise (leg bicycling with relaxed shoulders)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy treatment
Description: neck exercise strengthening program with neck massage

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy treatment
Description: neck exercise strengthening program with neck massage
Study: NCT03517215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced CB-ASP
Description: The education session will be a 1-hour on site presentation that will cover antimicrobial resistance, antimicrobial stewardship, an introduction to effective primary care interventions for reducing antibiotic prescribing, and a review of the clinic's baseline audit of antimicrobial prescribing for the prior year. E-Modules will be completed online and audit and feedback sessions will be held in person to give an overview of each clinic's prescribing numbers.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard CB-ASP
Description: A one hour introductory educational seminar will be offered to prescribers via a web-link. They will be provided with access to e-modules each month by email and sent their audit and feedback reports by email.
Study: NCT02820636

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: S-CBT
Description: The SCBT-SB protocol has 3 phases. Phase I, which is fixed (core sessions), includes 9 sessions (1 family, 5 individual \& 3 caretakers sessions). Topics include: understanding the suicidal crisis, identity in adolescence, chain analysis, communication skills, the power of thought and decision making, parenting skills, rearing in a different culture, and family communication. Phase II is flexible and consists of coping skills modules (thoughts, emotional regulation, social interactions, activities, substance abuse, family communication \& trauma). The treatment plan is adjusted to adolescents' needs. Family and primary caregiver sessions are flexible, depending on the family/caregivers' needs. Participants have received an adequate course of treatment if they at least complete the core sessions. This protocol should take 3-6 months. Once the active phase ends, booster sessions are recommended.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
Study: NCT02880761

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Assessment guiding surgery and puncture for AVF
Description: Assessment guiding surgery and puncture for AVF. Assessing the parameters of vascular vessels during following-up and making suggestions on surgery and puncture of AVF
Study: NCT03644693

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Formulation Containing Exogenous Ketones
Description: A nutritional formulation providing beta-hydroxybutyrate, 2g of carbohydrate, 1g of protein, and 9g of fat, plus minerals, per 100kcal. Given orally as food or beverage three times daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Formulation
Description: A placebo formulation providing similar amounts of carbohydrates, proteins and minerals as the nutritional formulation. Given orally as food or beverage three times daily.
Study: NCT00961207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
Study: NCT00859430

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: 1000 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra®
Description: 1000 mg Tablet
Study: NCT01537107

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies
Study: NCT02879396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PA4LE Program
Description: 1. Medication self-management including medication reconciliation, therapy recommendations, and education by pharmacist (chronic conditions and medications including Beers Criteria)~2. Use of a patient-centered health record that helps guide patients through the care process (portable, health and medication record for elders)~3. Primary care provider and specialist follow-up (patient awareness of discharge action plan and follow-up)~4. Patient understanding of red flag indicators of worsening condition and appropriate next steps~5. Behavioral interventions - Adherence, Lifestyle modifications, Mindfulness \& Lovingkindness meditations to combat anxiety, insomnia and other behavioral symptoms
Study: NCT03003299

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards SAPIEN 3/SAPIEN 3 Ultra THV
Description: Edwards SAPIEN 3/SAPIEN 3 Ultra THV system with the associated delivery systems.
Study: NCT01001299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug cocktail
Description: Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5185426
Description: 960 mg orally twice daily
Study: NCT04304547

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-828, D097, D337, CKD-348 T1, CKD-348 T2
Description: Subject of sequence A takes IP in the following order:~1. Each tablet of CKD-828 and D097 and D337 be taken at once~2. CKD-348 T1 1 tablet~3. CKD-348 T2 1 tabet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-348 T1, CKD-348 T2, CKD-828, D097, D337,
Description: Subject of sequence B takes IP in the following order:~1. CKD-348 T1 1 tablet~2. CKD-348 T2 1 tablet~3. Each tablet of CKD-828 and D097 and D337 be taken at once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CKD-348 T2, CKD-348 T1, CKD-828, D097, D337
Description: Subject of sequence C takes IP in the following order:~1. CKD-348 T2 1 tablet~2. Each tablet of CKD-828 and D097 and D337 be taken at once~3. CKD-348 T1 1 tablet
Study: NCT01836874

Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
Study: NCT02373501

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-abdominal repair
Description: Intra abdominal repair of uterine incision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Extra-abdominal repair
Description: Extra abdominal repair of uterine incision
Study: NCT03168529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules not containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
Study: NCT01817517

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Activa Deep Brain Stimulation System
Study: NCT03479645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Serial text messages and mailed FIT kit
Description: 1. Pre-alert SMS offering Opt-out of mailed FIT kit~2. Mailed home FIT kit~3. SMS A - Reciprocity message~4. SMS B - Offer for second FIT kit if lost/did not receive~   * Plus SMS A + C if second mailed FIT is requested.~5. SMS C - Salience message
Study: NCT00928122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Presbyopia
Description: Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal correction of Myopia
Description: Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Hyperopia
Description: Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Myopia incl. Astigmatism
Description: Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Hyperopia incl. Astigmatism
Description: Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
Study: NCT00575835

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D twice daily
Description: Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D3 oil three times in a year
Description: Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year